Depleting monoclonal antibodies against natural killer cells

JP2023549559A5Inactive Publication Date: 2024-11-22RGT UNIV OF CALIFORNIA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023529932
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-11-18
Filing Date
2021-11-15
Publication Date
2024-11-22
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Natural killer cells can target and kill activated T cells, which is beneficial in some cases but undesirable when T cells are needed to target cancer cells, as it limits the immune system's ability to kill cancer cells.

Method used

Administering an anti-CD94-specific antibody to deplete natural killer cells, potentially combined with checkpoint inhibitors, to enhance T cell-mediated cancer cell targeting.

Benefits of technology

Enhances the immune response against cancer by reducing natural killer cell-mediated elimination of activated T cells, allowing T cells to effectively target and kill cancer cells.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0001_ABST
    Figure 00000000_0001_ABST
  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

Anti-CD94 antibodies and uses thereof are described. TIFF2023549559000007.tif111132
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] Cross-reference to related patent applications This patent application claims the benefit of priority to U.S. Provisional Patent Application No. 63 / 115,180, filed November 18, 2020. U.S. Provisional Patent Application No. 63 / 115,180 is incorporated by reference. [Background technology]

[0002] Background of the Invention Certain specialized T cell groups play a key role in regulating and determining immune responses by performing various immune-related functions. One of these functions is immune-mediated cell death, which is carried out by T cells in several ways. Specifically, CD8+ T cells, also known as "killer cells," are cytotoxic. This means that CD8+ T cells can directly kill virus-infected cells as well as cancer cells. CD8+ T cells can also utilize small signaling proteins known as cytokines to recruit other cells at the initiation of an immune response. A different T cell population, CD4+ T cells, function as "helper cells." Unlike CD8+ killer T cells, these CD4+ helper T cells typically function by indirectly killing cells identified as foreign. That is, CD4+ T cells determine whether and how the rest of the immune system responds to a specific perceived threat. There is also evidence that CD4+ T cells can directly kill virus-infected or cancer cells.

[0003] Cancer immunotherapy can involve the activation and expansion of natural, engineered, or exogenous cancer-specific T cells that kill cancer cells by recognizing antigenic targets expressed on the cancer cells. However, the immune system has means to regulate itself to avoid an overly activated response, which can limit the immune system's ability to kill cancer cells. Summary of the Invention

[0004] Brief Summary of the Invention In some embodiments, there are methods for enhancing T cell responses in an individual in need thereof. In some embodiments, the method comprises administering to the individual an antibody (human, humanized, chimeric, or synthetic) specific for natural killer (NK) cells in an amount sufficient to eliminate at least some of the natural killer cells, thereby preventing or reducing killing of activated T cells by natural killer cells. In some embodiments, the method comprises administering to the individual an anti-CD94-specific antibody (human, humanized, chimeric, or synthetic) in an amount sufficient to eliminate at least some of the natural killer cells, thereby preventing or reducing killing of activated T cells by natural killer cells. In some embodiments, the individual has cancer and activated T cells in the individual that target cancer cells in the individual.

[0005] In some embodiments, the method further comprises administering one or more checkpoint inhibitors before, after, or simultaneously with administering the antibody (e.g., an anti-CD94 specific antibody) to the individual. In some embodiments, the checkpoint inhibitor is an anti-CTLA-4, anti-PD-1, or anti-PD-L1 antibody.

[0006] In some embodiments, the anti-CD94 specific antibody is Respectfully, a heavy chain variable region comprising heavy chain complementarity determining region (CDR) 1, CDR2, and CDR3 of SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3; and Respectfully, a light chain variable region comprising light chain CDR1, CDR2, and CDR3 of SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6; or Respectfully, a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 of SEQ ID NO:7, SEQ ID NO:8, and SEQ ID NO:9; and Respectfully, the light chain variable regions comprising light chain CDR1, CDR2, and CDR3 of SEQ ID NO:10, SEQ ID NO:11, and SEQ ID NO:12 Includes.

[0007] In some aspects, the antibody is a chimeric antibody. In some aspects, the chimeric antibody is a humanized antibody. In some aspects, the antibody is a human antibody or a synthetic antibody.

[0008] In some embodiments, the anti-CD94 specific antibody is a heavy chain variable region comprising SEQ ID NO:13 and a light chain variable region comprising SEQ ID NO:14; or A heavy chain variable region comprising SEQ ID NO:15 and a light chain variable region comprising SEQ ID NO:16 Includes.

[0009] In some embodiments, the antibody induces antibody-dependent cellular cytotoxicity (ADCC) or antibody-dependent phagocytosis (ADP) against natural killer cells that express the CD94 protein. In some embodiments, the antibody is linked to a toxin to eliminate cells that express the CD94 protein.

[0010] In some embodiments, the methods include administering to the individual an anti-NK cell (e.g., anti-CD94 specific) antibody in an amount sufficient to transiently deplete natural killer cells, such that the natural killer cells do not respond to and kill allogeneic or xenogeneic cells or tissues introduced into the individual.

[0011] In some embodiments, the allogeneic or xenogeneic cells are CAR-T cells.

[0012] In some embodiments, the cells transplanted into the individual are allogeneic cells, where the allogeneic cells lack HLA class I proteins. In some embodiments, the transplanted cells comprise an introduced genetic alteration that prevents or reduces CD94 expression on the transplanted cells.

[0013] In some aspects, the individual has cancer.

[0014] In some embodiments, the anti-CD94 specific antibody is Respectfully, a heavy chain variable region comprising heavy chain complementarity determining region (CDR) 1, CDR2, and CDR3 of SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3; and Respectfully, a light chain variable region comprising light chain CDR1, CDR2, and CDR3 of SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6; or Respectfully, a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 of SEQ ID NO:7, SEQ ID NO:8, and SEQ ID NO:9; and Respectfully, the light chain variable regions comprising light chain CDR1, CDR2, and CDR3 of SEQ ID NO:10, SEQ ID NO:11, and SEQ ID NO:12 Includes.

[0015] In some aspects, the antibody is a chimeric antibody. In some aspects, the chimeric antibody is a humanized antibody. In some aspects, the antibody is a human antibody or a synthetic antibody.

[0016] In some embodiments, the anti-CD94 specific antibody is a heavy chain variable region comprising SEQ ID NO:13 and a light chain variable region comprising SEQ ID NO:14; or A heavy chain variable region comprising SEQ ID NO:15 and a light chain variable region comprising SEQ ID NO:16 Includes.

[0017] In some embodiments, the antibody induces antibody-dependent cellular cytotoxicity (ADCC) or antibody-dependent phagocytosis of natural killer cells that express an NK-specific target protein (e.g., CD94). In some embodiments, the antibody is linked to a toxin to eliminate cells that express an NK-specific target protein (e.g., CD94).

[0018] Also provided are methods for reducing or preventing natural killer cell rejection of allogeneic cell or tissue transplants in an individual. In some embodiments, the methods include administering to the individual, before or after transplantation, an antibody specific for an NK-specific target protein (e.g., an anti-CD94-specific antibody) in an amount sufficient to temporarily deplete natural killer cells or other cells expressing an NK-specific target protein (e.g., CD94 protein). In some embodiments, the antibody specific for the NK-specific target protein (e.g., an anti-CD94-specific antibody) is administered before transplantation, and then allogeneic or xenogeneic cells or tissues are transplanted into the individual while natural killer cells or cells expressing CD94 protein are depleted.

[0019] In some embodiments, the cells transplanted into the individual are allogeneic cells, where the allogeneic cells lack one or more HLA class I proteins. In some embodiments, the transplanted cells comprise an introduced genetic alteration that prevents or reduces expression of an NK-specific target protein (e.g., CD94) on the transplanted cells.

[0020] In some aspects, the anti-CD94 antibody is Respectfully, a heavy chain variable region comprising heavy chain complementarity determining region (CDR) 1, CDR2, and CDR3 of SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3; and Respectfully, a light chain variable region comprising light chain CDR1, CDR2, and CDR3 of SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6; or Respectfully, a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 of SEQ ID NO:7, SEQ ID NO:8, and SEQ ID NO:9; and Respectfully, the light chain variable regions comprising light chain CDR1, CDR2, and CDR3 of SEQ ID NO:10, SEQ ID NO:11, and SEQ ID NO:12 Includes.

[0021] In some aspects, the antibody is a chimeric antibody. In some aspects, the chimeric antibody is a humanized antibody. In some aspects, the antibody is a human antibody or a synthetic antibody.

[0022] In some aspects, the anti-CD94 antibody is a heavy chain variable region comprising SEQ ID NO:13 and a light chain variable region comprising SEQ ID NO:14; or A heavy chain variable region comprising SEQ ID NO:15 and a light chain variable region comprising SEQ ID NO:16 Includes.

[0023] In some embodiments, the antibody induces antibody-dependent cellular cytotoxicity (ADCC) or antibody-dependent phagocytosis (ADP) of natural killer cells that express the CD94 protein. In some embodiments, the antibody is linked to a toxin to eliminate cells that express the CD94 protein.

[0024] Monoclonal antibodies that bind to CD94 are also provided. In some embodiments, the antibodies Respectfully, a heavy chain variable region comprising heavy chain complementarity determining region (CDR) 1, CDR2, and CDR3 of SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3; and Respectfully, a light chain variable region comprising light chain CDR1, CDR2, and CDR3 of SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6; or Respectfully, a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 of SEQ ID NO:7, SEQ ID NO:8, and SEQ ID NO:9; and Respectfully, the light chain variable regions comprising light chain CDR1, CDR2, and CDR3 of SEQ ID NO:10, SEQ ID NO:11, and SEQ ID NO:12 Includes.

[0025] In some aspects, the antibody is a chimeric antibody. In some aspects, the chimeric antibody is a humanized antibody.

[0026] In some aspects, the anti-CD94 antibody is a heavy chain variable region comprising SEQ ID NO:13 and a light chain variable region comprising SEQ ID NO:14; or A heavy chain variable region comprising SEQ ID NO:15 and a light chain variable region comprising SEQ ID NO:16 Includes.

[0027] definition As used herein, the terms "a," "an," and "the" not only include aspects with one member, but also aspects with multiple members. For example, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a cell" includes a plurality of such cells, and reference to "the agent" includes reference to one or more agents known to those of skill in the art.

[0028] As used herein, the term "antibody" includes multimeric (e.g., tetrameric) and single-domain antibodies, as well as antibody fragments, that retain binding specificity. Antibodies described herein may consist of one or more polypeptides substantially encoded by immunoglobulin genes or fragments of immunoglobulin genes. Recognized immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon, and mu constant region genes, as well as the myriad immunoglobulin variable region genes. Light chains are classified as either kappa or lambda. Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, which in turn define the immunoglobulin classes IgG, IgM, IgA, IgD, and IgE, respectively. In some embodiments, the antibody is an IgG (e.g., IgG1, IgG2, IgG3, IgG4), IgM, IgA, IgD, or IgE.

[0029] One exemplary immunoglobulin (antibody) structural unit comprises a tetramer. Each tetramer is composed of two identical pairs of polypeptide chains, each pair having one "light" chain (about 25 kD) and one "heavy" chain (about 50-70 kD). The N-terminus of each chain defines a variable region of about 100-110 or more amino acids that is primarily responsible for antigen recognition. The variable light chain (V L ) and variable heavy chain (V H ) refer to these light and heavy chains respectively.

[0030] There are many well-characterized antibody fragments. Thus, for example, pepsin digests tetrameric antibodies at the C-terminal side of the disulfide bond in the hinge region to produce F(ab)'2, a Fab dimer in which the light chain and VH-CH1 are linked by a disulfide bond. F(ab)'2 can be reduced under mild conditions to cleave the disulfide bond in the hinge region, thereby converting the (Fab')2 dimer into a Fab' monomer. Fab' monomers are essentially Fab with part of the hinge region (for a more detailed description of other antibody fragments, see *Fundamental Immunology*, W.E. Paul, ed., Raven Press, NY (1993)). While various antibody fragments have been defined in terms of the digestion of intact antibodies, those skilled in the art will understand that fragments can be synthesized de novo either chemically or by using recombinant DNA methodology. Thus, the term antibody, as used herein, also includes antibody fragments produced by modifying whole antibodies or synthesized using recombinant DNA methodology.

[0031] In addition to the specific antibody sequences provided herein, antibody substitution variants are also contemplated. Substitution variants may have at least one amino acid residue removed and a different residue inserted in its place. The most interesting sites for substitution mutagenesis include hypervariable regions, but framework changes are also contemplated.

[0032] Substantial alteration of the biological properties of the antibody is achieved by selecting substitutions that differ significantly in their effect on (a) the structure of the polypeptide backbone in the region of substitution, e.g., in a beta-sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) maintaining the bulk of the side chain. Natural residues are grouped into the following groups based on common side chain properties: (1) Nonpolar: Norleucine, Met, Ala, Val, Leu, Ile; (2) uncharged and polar: Cys, Ser, Thr, Asn, Gln; (3) Acidic (negatively charged): Asp, Glu; (4) Basic (positively charged): Lys, Arg; (5) residues that influence chain orientation: Gly, Pro; and (6) Aromatic: Trp, Tyr, Phe, His Non-conservative substitutions are made by exchanging a member of one of these classes for a member of another class.

[0033] One type of substitution that can be made is to change one or more chemically reactive cysteines in the antibody to another residue, such as, but not limited to, alanine or serine. For example, there can be a non-classical cysteine ​​substitution. This substitution can be made in the CDR or framework region of the variable domain, or in the constant region of the antibody. In some embodiments, the cysteine ​​is classical (e.g., involved in disulfide bond formation). Any cysteine ​​residue not involved in maintaining the correct conformation of the antibody can typically be substituted with serine to improve the oxidative stability of the molecule and prevent aberrant cross-linking. Conversely, cysteine ​​bond(s) can be added to an antibody to improve its stability, especially when the antibody is an antibody fragment such as an Fv fragment.

[0034] Antibodies include single chain antibodies (antibodies that exist as a single polypeptide chain), e.g., V antibodies, including single chain Fv antibodies (sFv or scFv), in which the variable heavy and variable light chain regions are linked (directly or via a peptide linker) to form a contiguous polypeptide. H -V L Single-chain Fv antibodies can include V dimers, either directly linked or linked by a peptide-encoding linker. H Coding sequence and V L A covalently linked V that can be expressed from a nucleic acid containing a coding sequence H -V L (e.g., Huston, et al. Proc. Nat. Acad. Sci. USA, 85:5879-5883, 1988). H and V L are connected to each other as a single polypeptide chain, while V H Domains and V L The domains are non-covalently associated. Alternatively, the antibody may be another fragment. Other fragments can be produced, for example, using recombinant methods, as soluble proteins, or as fragments obtained from display methods. Antibodies may also include diantibodies and miniantibodies. As mentioned above, antibodies also include single domain antibodies, for example, heavy chain dimers, for example, antibodies derived from camelids.

[0035] As used herein, a "chimeric antibody" refers to (a) an immunoglobulin molecule in which the constant region or a portion thereof has been altered, substituted, or exchanged so that the antigen-binding site (variable region) is linked to a constant region of a different or altered class, effector function, and / or species, or to an entirely different molecule that confers new properties to the chimeric antibody, such as an enzyme, toxin, hormone, growth factor, drug, etc., or (b) an immunoglobulin molecule in which the variable region or a portion thereof has been altered, substituted, or exchanged with a variable region or portion thereof having a different or altered antigen specificity or with the corresponding sequence from another species or another antibody class or subclass.

[0036] As used herein, "humanized antibody" refers to an immunoglobulin molecule in which CDRs from a donor antibody have been grafted onto human framework sequences, or where non-human framework regions have been modified to contain human amino acid residues. A humanized antibody may also contain donor-derived residues in the framework sequences. A humanized antibody may also contain at least a portion of a human immunoglobulin constant region. A humanized antibody may also contain residues that are found neither in the recipient antibody nor in the imported CDRs or framework sequences. Humanization can be performed by methods known in the art (e.g., Jones et al., Nature 321:522-525; 1986; Riechmann et al., Nature 332:323-327, 1988; Verhoeyen et al., Science 239:1534-1536, 1988); Presta, Curr. Op. Struct. Biol. 2:593-596, 1992; Presta, Curr. Op. Struct. Biol. 2:593-596, 1992), including techniques such as "superhumanized" antibodies (Tan et al., J. Immunol. 169:1119, 2002) and "resurfacing" (e.g., Staelens et al., Mol. Immunol. 43:1243, 2006; and Roguska et al., Proc. Natl. Acad. Sci USA 91:969, 1994). This can be accomplished using methods such as those described in U.S. Pat. No. 4,816,567.

[0037] As used herein, "complementarity determining region (CDR)" refers to the three hypervariable regions (HVRs) that interrupt the four "framework" regions of a variable region. The CDRs are primarily responsible for binding to an antigen epitope. The CDRs are designated CDR1, CDR2, and CDR3 and are numbered consecutively, starting from the N-terminus. The term "CDR" is sometimes used interchangeably with "HVR."

[0038] The amino acid sequences of the CDRs and framework regions can be determined using various definitions well known in the art, such as Kabat, Chothia, the international ImMunoGeneTics database (IMGT), and AbM (see, e.g., Johnson et al., supra; Chothia & Lesk, 1987, Canonical structures for the hypervariable regions of immunoglobulins. J. Mol. Biol. 196, 901-917; Chothia C. et al., 1989, Conformations of immunoglobulin hypervariable regions. Nature 342, 877-883; Chothia C. et al., 1992, structural repertoire of the human VH segments J. Mol. Biol. 227, 799-817; Al-Lazikani et al., J. Mol. Biol 1997, 273(4)).The definition of an antigen-binding site is also found in the following: Ruiz et al., IMGT, the international ImMunoGeneTics database. Nucleic Acids Res., 28, 219-221 (2000); and Lefranc, M.-P. IMGT, the international ImMunoGeneTics database. Nucleic Acids Res. Jan 1;29(1):207-9 (2001); MacCallum et al, Antibody-antigen interactions: Contact analysis and binding site topography, J. Mol. Biol., 262 (5), 732-745 (1996); and Martin et al, Proc. Natl Acad. Sci. USA, 86, 9268-9272 (1989); Martin, et al, Methods Enzymol., 203, 121-153, (1991); Pedersen et al, Immunomethods, 1, 126, (1992); and Rees et al., In Sternberg MJE (ed.), Protein Structure Prediction. Oxford University Press, Oxford, 141-172 1996. References to CDRs determined by Kabat numbering are based on, for example, Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD (1991)). Chothia CDRs are determined as defined by Chothia (see, for example, Chothia and Lesk J. Mol. Biol. 196:901-917 (1987)).

[0039] "Epitope" or "antigenic determinant" refers to the site on an antigen to which an antibody binds. Epitopes can be formed from both contiguous amino acids or noncontiguous amino acids juxtaposed by tertiary folding of a protein. Epitopes formed from contiguous amino acids are typically retained upon exposure to denaturing solvents, whereas epitopes formed by tertiary folding are typically lost upon treatment with denaturing solvents. Epitopes typically comprise at least three, more usually at least five or eight to ten, amino acids in a unique spatial conformation. Methods for determining the spatial conformation of epitopes include, for example, X-ray crystallography and two-dimensional nuclear magnetic resonance. See, for example, Epitope Mapping Protocols in Methods in Molecular Biology, Vol. 66, Glenn E. Morris, Ed. (1996).

[0040] As used herein, the term "valency" refers to the number of different binding sites of an antibody for an antigen. A monovalent antibody contains one binding site for an antigen. A multivalent antibody contains multiple binding sites.

[0041] The phrases "specifically (or selectively) bind" or "specifically (or selectively) immunoreact with" an antigen or target, when referring to a protein or peptide, refer to a binding reaction in which an antibody binds to the antigen or target of interest. In the context of this disclosure, the antibody has a K that is at least 100 times greater than its affinity for other antigens (e.g., CD20, for example). D Binds to human CD94 virus.

[0042] The term "identical" or percent "identity," in the context of two or more polypeptide sequences, refers to two or more sequences or subsequences that, when compared and aligned for maximum correspondence over a comparison window or designated region, are the same or have a specified percentage (e.g., at least 70%, at least 75%, at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) of identical amino acid residues over a designated region. Alignment for purposes of determining percent amino acid sequence identity can be performed using publicly available computer software such as BLAST-2.0. The BLAST and BLAST 2.0 algorithms are described in Altschul et al., Nuc. Acids Res. 25:3389-3402 (1977) and Altschul et al., J. Mol. Biol. 215:403-410 (1990). Thus, BLAST 2.0 can be used with default parameters to determine percent sequence identity.

[0043] The terms "corresponding to," "determined with respect to," or "numbered with respect to," when used in the context of identifying a particular amino acid residue in a polypeptide sequence, refer to the residue position of the specified reference sequence when a particular amino acid sequence is maximally aligned or compared to the reference sequence. Thus, for example, an amino acid residue in a variable domain polypeptide, when optimally aligned with a sequence and aligned with the amino acids in that sequence, "corresponds to" an amino acid in a polypeptide described herein. A polypeptide that is aligned with a reference sequence need not be the same length as the reference sequence.

[0044] As used herein, "conservative" substitution refers to amino acid substitution that maintains the charge, hydrophobicity, and / or size of side chain.Exemplary amino acid sets that can be substituted for each other include: (i) positively charged amino acids Lys, Arg, and His; (ii) negatively charged amino acids Glu and Asp; (iii) aromatic amino acids Phe, Tyr, and Trp; (iv) nitrogen ring amino acids His and Trp; (v) large aliphatic non-polar amino acids Val, Leu, and Ile; (vi) slightly polar amino acids Met and Cys; (vii) small side chain amino acids Ser, Thr, Asp, Asn, Gly, Ala, Glu, Gln, and Pro; (viii) aliphatic amino acids Val, Leu, Ile, Met, and Cys; and (ix) small hydroxyl amino acids Ser and Thr.In this paragraph, the reference to the charge of amino acid refers to the charge at physiological pH.

[0045] The terms "nucleic acid" and "polynucleotide" are used interchangeably and, as used herein, refer to both sense and antisense strands of RNA, cDNA, genomic DNA, and synthetic forms and mixed polymers of the above. In certain embodiments, nucleotides refer to ribonucleotides, deoxynucleotides, or modified forms of either nucleotide type, or combinations thereof. This term includes, but is not limited to, single-stranded and double-stranded forms of DNA. Furthermore, polynucleotides, such as cDNA or mRNA, may contain either or both natural and modified nucleotides linked together by natural and / or non-natural nucleotide linkages. As will be readily understood by those skilled in the art, nucleic acid molecules may be chemically or biochemically modified and may contain non-natural or derivatized nucleotide bases. Such modifications include, for example, labels, methylation, substitution of one or more of the natural nucleotides with analogs, internucleotide modifications such as uncharged bonds (e.g., methylphosphonates, phosphotriesters, phosphoramidates, carbamates, etc.), charged bonds (e.g., phosphorothioates, phosphorodithioates, etc.), pendant moieties (e.g., polypeptides), intercalators (e.g., acridine, psoralens, etc.), chelators, alkylators, and modified linkages (e.g., α-anomeric nucleic acids, etc.). The above terms are also intended to include any topological conformation, including single-stranded, double-stranded, partially double-stranded, triple-stranded, hairpin, circular, and padlocked conformations. A reference to a nucleic acid sequence includes its complementary strand unless otherwise specified. Thus, a reference to a nucleic acid molecule having a particular sequence should be understood to include its complementary strand, having its complementary sequence. The term also includes codon-optimized nucleic acids encoding the same polypeptide sequence.

[0046] The terms "subject," "patient," or "individual" are used interchangeably herein to refer to any mammal, including, but not limited to, a human. For example, an animal subject may be a primate (e.g., monkey, chimpanzee), livestock (e.g., horse, cow, sheep, pig, or goat), companion animal (e.g., dog, cat), laboratory animal (e.g., mouse, rat, guinea pig), or any other mammal. In some embodiments, a "subject," "patient," or "individual" is a human.

[0047] As used herein, the term "therapeutically effective dose," "effective dose," or "therapeutically effective amount" refers to a dose that produces an effect for which it is administered. The exact dosage and formulation depend on the purpose of treatment and can be determined by those skilled in the art using known techniques (see, for example, Lieberman, Pharmaceutical Dosage Forms (vols. 1-3, 1992); Lloyd, The Art, Science and Technology of Pharmaceutical Compounding (1999); Remington: The Science and Practice of Pharmacy, 20th Edition, Gennaro, Editor (2003), and Pickar, Dosage Calculations (1999)). For example, for a particular parameter, a therapeutically effective amount represents an increase or decrease in the therapeutic effect of at least 5%, 10%, 15%, 20%, 25%, 40%, 50%, 60%, 75%, 80%, 90%, or at least 100%. Therapeutic efficacy can also be expressed as a "fold" increase or decrease. For example, a therapeutically effective amount may have at least a 1.2-fold, 1.5-fold, 2-fold, 5-fold, or greater effect compared to a control.

[0048] As used herein, the phrase "T cells" refers to human lymphoid cells that express T cell receptor molecules. T cells include human alpha beta (αβ) T cells and human gamma delta (γδ) T cells. T cells include, but are not limited to, naive T cells, stimulated T cells, primary T cells (e.g., uncultured), cultured T cells, immortalized T cells, helper T cells, cytotoxic T cells, memory T cells, regulatory T cells, natural killer T cells, combinations thereof, or subpopulations thereof. T cells are CD4 + , CD8 + , or CD4 + and CD8 + , or CD4 - , or CD8 - T cells may be helper cells, e.g., T H 1. T H 2. T H 3. T H 9. T H 17, or T FH The T cells may be cytotoxic T cells. The regulatory T cells may be FOXP3 + or FOXP3 - The T cells may be alpha / beta T cells or gamma / delta T cells. In some cases, the T cells are CD4 + CD25 hi CD127 lo Regulatory T cells. In some cases, T cells are classified as type 1 regulatory (Tr1), T H 3. CD8 + CD28 - , and Treg17 T cells, or a combination or subpopulation thereof. Optionally, the T cells are human regulatory T cells selected from the group consisting of FOXP3 + T cells. In some cases, T cells are CD4 + CD25 lo CD127 hi effector T cells. In some cases, T cells are CD4 + CD25 lo CD127 hi CD45RA hi CD45RO -The T cells are naive T cells. The T cells may be genetically engineered T cells. In some cases, the T cells have a recombinant (e.g., heterologous) T cell receptor.

[0049] Natural killer cells, also known as NK cells, are a type of cytotoxic lymphocyte involved in the innate immune system. NK cells can be identified by the presence of CD56 and the absence of CD3 (CD56+, CD3-). See, for example, Pfefferle A, et al., (2020). "Deciphering Natural Killer Cell Homeostasis". Frontiers in Immunology. 11: 812; Schmidt S, et al., (2018). "Natural killer cells as a therapeutic tool for infectious diseases - current status and future perspectives". Oncotarget. 9 (29): 20891-20907. CD94 is primarily expressed on NK cells (see, for example, Guntauri et al., Immunol Res 30(1):29-34 (2004)) and is considered relatively NK cell-specific in the context of the present disclosure. Human CD94 is described, for example, in Chang et al., Eur. J. Immonol. 25:2433-2437 (1995) Uniprot Q13241 and occurs in at least nine different isoforms (GenBank accession numbers: NM_007334.3, NM_001351062.2, NM_001351060.2, NM_001114396.3, NM_001351063.2, NM_002262.5, NR_147038.2, NR_147039.2, and NR_147040.2).

[0050] The terms "pharmaceutically acceptable salts" or "pharmaceutically acceptable carriers" or "pharmaceutically acceptable excipients" are meant to include salts of active compounds prepared using relatively non-toxic acids or bases, depending on the particular substituents found on the antibodies described herein. Examples of pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amino, or magnesium salts, or similar salts. When a compound of the present invention contains a relatively basic functional group, an acid addition salt can be obtained by contacting the neutral form of such a compound, neat or dissolved in a suitable inert solvent, with a sufficient amount of the desired acid. Examples of pharmaceutically acceptable acid addition salts include acid addition salts derived from inorganic acids such as hydrochloric acid, hydrobromic acid, nitric acid, carbonic acid, monohydrogencarbonic acid, phosphoric acid, monohydrogenphosphoric acid, dihydrogenphosphoric acid, sulfuric acid, monohydrogensulfuric acid, hydroiodic acid, or phosphorous acid, as well as salts derived from relatively non-toxic organic acids such as acetic acid, propionic acid, isobutyric acid, maleic acid, malonic acid, benzoic acid, succinic acid, suberic acid, fumaric acid, lactic acid, mandelic acid, phthalic acid, benzenesulfonic acid, p-tolylsulfonic acid, citric acid, tartaric acid, methanesulfonic acid, and the like. Also included are salts of amino acids, such as arginate, and salts of organic acids, such as glucuronic acid or galacturonic acid (see, e.g., Berge et al., Journal of Pharmaceutical Science 66:1-19 (1977)). Certain compounds of the present invention contain both basic and acidic functional groups that allow them to be converted into either base or acid addition salts. Other pharmaceutically acceptable carriers known to those skilled in the art are suitable for the present disclosure. [Brief explanation of the drawings]

[0051] [Figure 1]Results from multiple rounds of enrichment of Fab phages that bind to CD94 Fc fusion proteins. The extracellular domain (ECD) of human CD94 was expressed in mammalian cells as an Fc fusion protein. The Fc fusion protein contains a biotin acceptor tag at its N-terminus and a TEV proteolysis site between the ECD and Fc domain. These tags facilitate the "catch-and-release" process in phage display selection, ensuring the selective release of Fab phages that bound to the CD94 Fc fusion protein. Selected Fab phages were propagated in E. coli, purified, and then subjected to another round of selection. CD94 antibody selection was repeated four times. Figure 1 shows the Fab phage enrichment ratios from rounds 2 to 4. Selections for GFP and a negative control (PBS buffer only) were performed in the same selection campaign using CD94 Fc-fusion proteins. [Figure 2] 2A-B show the binding curves of the anti-CD94 antibodies JLS002-rAB22 and JLS002-rAB23. [Figure 3] FIG. 3 shows the results from an octet assay used to detect the affinity of IgG for two anti-CD94 binders, JLS002-rAB22 and JLS002-rAB23. [Figure 4A] FIG. 4A shows staining of Ba / F3 transfectants expressing human CD94. [Figure 4B] FIG. 4B shows staining of Ba / F3 transfectants expressing human CD94, NKG2D, and DAP12. [Figure 5] Figures 5A-B show that depleting NK cells improves the efficacy of α-PD-1L checkpoint blockade treatment against RMA lymphoma growth. Figure 5A) Experimental design. Figure 5B) Measurement of tumor burden over time. Intraperitoneal injections of α-NK1.1, α-PD-1L, and an IgG2b isotype-matched control antibody at concentrations of 150 μg, 250 μg, and 250 μg were injected at the indicated time points. Significance is indicated by Student's t-test, with *P<0.05. DETAILED DESCRIPTION OF THE INVENTION

[0052] Detailed Description of the Invention The present inventors have determined that natural killer cells can target and kill highly activated T cells. While this may be beneficial in many cases (e.g., to block an overly active immune response), in some embodiments, this effect is undesirable. For example, in some embodiments, it is desirable to use T cells to target cancer cells or other undesirable agents within an individual. In these aspects, activated T cells (e.g., CD8 + It may be advantageous to deplete natural killer cells in an individual to enable T cells (effector T cells) to target and kill cancer cells in the individual. Thus, in some embodiments, an anti-CD94 antibody is administered to an individual with cancer to deplete natural killer cells, thereby enhancing targeting of cancer cells in the individual by T cells that would otherwise be eliminated by natural killer cells. This method may further include administering one or more checkpoint inhibitors. Thus, an enhanced immune response against cancer can be induced. In some embodiments, administration of an anti-CD94 antibody or an antibody that preferentially targets natural killer cells may be accompanied by, followed by, or preceded by administration of an antigen that activates T cells against one or more cancer antigens.

[0053] The inventors have also discovered that NK cell-mediated immune responses against non-self cells or tissues in an individual can be reduced by (i) administering to the individual an antibody specific for an NK-specific target protein (e.g., an anti-CD94-specific antibody) in an amount sufficient to temporarily deplete natural killer cells, and (ii) transplanting non-self cells or tissues into the individual. Expression of the non-self cells or tissues may be performed first before or after administration of the antibody (e.g., an anti-CD94 antibody). Exemplary non-self cells or tissues may include, but are not limited to, chimeric antigen receptor (CAR) T cells (including, but not limited to, autologous or allogeneic T cells modified to express a non-self CAR), or T cells expressing a heterologous T cell receptor (including, but not limited to, autologous or allogeneic T cells).

[0054] In yet other embodiments, the NK cell-mediated immune response against autologous cells reintroduced into an individual can be reduced by (i) administering to the individual an anti-CD94-specific antibody or an antibody that preferentially binds to natural killer cells in an amount sufficient to transiently deplete natural killer cells, and (ii) introducing cancer-specific T cells into the individual, where the introduced cells are generated by obtaining cells from the individual and expanding and / or enriching the cancer-specific T cells ex vivo.

[0055] Exemplary CD94 antibodies include antibodies that specifically bind to the extracellular domain of CD94 and, optionally, do not bind to NKG2A or NKG2C. The antibodies have sufficiently high affinity (low K D In some embodiments, the K D is 10 -7 M or less, 10 -8 M or less, 10 -9 M or less, or 10 -10 M or less, e.g., 10 -8 M~10 -10 M or 10 -8 M~10 -11 I am M.

[0056] In some aspects, the anti-CD94 antibody comprises a heavy chain variable region comprising heavy chain complementarity determining regions (CDRs) 1, 2, and 3 of VYSSSI (SEQ ID NO:1), YISSYSGYTY (SEQ ID NO:2), and GRYQGM (SEQ ID NO:3), respectfully, and a light chain variable region comprising light chain CDRs 1, 2, and 3 of SVSSA (SEQ ID NO:4), SASSLYS (SEQ ID NO:5), and YAYHLI (SEQ ID NO:6). a heavy chain variable region comprising TIFF2023549559000002.tif18159; and a light chain variable region comprising TIFF2023549559000003.tif11159.

[0057] In some embodiments, the anti-CD94 antibody comprises a heavy chain variable region comprising the heavy chain CDR1, CDR2, and CDR3 of, respectfully, VYSSSI (SEQ ID NO:7), SISSYSGSTS (SEQ ID NO:8), and YGYYMSGAM (SEQ ID NO:9), and a light chain variable region comprising the light chain CDR1, CDR2, and CDR3 of, respectfully, SVSSA (SEQ ID NO:10), SASSLYS (SEQ ID NO:11), and KKAYSLI (SEQ ID NO:12). a heavy chain variable region comprising TIFF2023549559000004.tif18160; and a light chain variable region comprising TIFF2023549559000005.tif11159. Other CD94-specific antibodies can also be used.

[0058] In some embodiments, two or more different CD94 antibodies are administered, where the two antibodies bind to different epitopes on the surface of CD94. For example, in some embodiments, one or both of the two antibodies are selected from those described above.

[0059] One method for preparing the antibodies described herein involves expressing nucleic acid encoding the antibody in a suitable host cell or host organism, or in another suitable expression system, and optionally subsequently isolating and / or purifying the antibody. The antibodies, including binding fragments and other derivatives thereof, can be produced by a variety of recombinant DNA methods, including expression in transfected cells (e.g., immortalized eukaryotic cells, such as myeloma or hybridoma cells). Suitable source cells of DNA sequences and host cells for immunoglobulin expression and secretion are available from a number of sources, for example, the American Type Culture Collection (Catalogue of Cell Lines and Hybridomas, Fifth edition (1985) Rockville, Md.).

[0060] In some embodiments, the antibody is a humanized antibody, i.e., an antibody that has reduced immunogenicity in humans but retains the reactivity of a non-human antibody. This can be achieved, for example, by retaining the non-human CDR regions and replacing the remainder of the antibody with its human counterpart. See, e.g., Morrison et al., PNAS USA, 81:6851-6855 (1984); Morrison and Oi, Adv. Immunol., 44:65-92 (1988); Verhoeyen et al., Science, 239:1534-1536 (1988); Padlan, Molec. Immun., 28:489-498 (1991); Padlan, Molec. Immun., 31(3):169-217 (1994). Techniques for humanizing antibodies are well known in the art and are described, for example, in U.S. Pat. Nos. 4,816,567; 5,530,101; 5,859,205; 5,585,089; 5,693,761; 5,693,762; 5,777,085; 6,180,370; 6,210,671; and 6,329,511; WO 87 / 02671; EP Patent Application 0173494; Jones et al. (1986) Nature 321:522; and Verhoyen et al. (1988) Science 239:1534. Humanized antibodies are further described, for example, in Winter and Milstein (1991) Nature 349:293. For example, a polynucleotide comprising a first set of sequences encoding a humanized immunoglobulin framework region and a second set of sequences encoding the desired immunoglobulin complementarity-determining regions can be produced synthetically or by combining appropriate cDNA and genomic DNA segments. Human constant region DNA sequences can be isolated from a variety of human cells according to well-known procedures.

[0061] In some cases, transferring CDRs into human frameworks can cause the specificity of humanized antibodies to be lost.In these cases, back mutations can be introduced into the framework region of the human part of the antibody.Methods for adding back mutations are described, for example, in Co et al., PNAS USA 88;2269-2273(1991) and WO90 / 07861.

[0062] In some embodiments, the antibody is an antibody fragment such as Fab, F(ab')2, Fv, or scFv. Antibody fragments can be produced using any means known in the art, including chemical digestion (e.g., papain or pepsin) and recombinant methods. Methods for isolating and preparing recombinant nucleic acids are known to those of skill in the art (see Sambrook et al., Molecular Cloning. A Laboratory Manual (2d ed. 1989); Ausubel et al., Current Protocols in Molecular Biology (1995)). The antibody can be expressed in a variety of host cells, including E. coli, other bacterial hosts, yeast, and various higher eukaryotic cells, such as COS, CHO, and HeLa cell lines and myeloma cell lines.

[0063] Competitive binding assays can be used to identify antibodies that compete with the antibodies described herein for specific binding, for example, to CD94. Any of the numerous competitive binding assays known in the art can be used to measure competition between two antibodies for the same antigen. Briefly, the ability of different antibodies to inhibit the binding of another antibody is tested. For example, a sandwich ELISA assay can be used to differentiate antibodies based on the epitope to which they bind. This is done by coating the well surface with a capture antibody. A subsaturating concentration of tagged antigen is then added to the capture surface. This protein binds to the antibody through a specific antibody:epitope interaction. After washing, a second antibody covalently linked to a detectable moiety (e.g., HRP; the labeled antibody is defined as the detection antibody) is added to the ELISA. If this antibody recognizes the same epitope as the capture antibody, it will not be able to bind to the target protein because the specific epitope is no longer available for binding. However, if this second antibody recognizes a different epitope on the target protein, binding is possible, and this binding can be detected by quantifying the activity level (and therefore the bound antibody) using the relevant substrate. Background is defined by using one antibody as both the capture and detection antibody, while maximum signal can be established by capturing with an antigen-specific antibody and detecting with an antibody against a tag on the antigen. By using background and maximum signal as standards, antibodies can be evaluated in pairs to confirm epitope specificity.

[0064] A first antibody is considered to competitively inhibit the binding of a second antibody if the binding of the second antibody to the antigen in the presence of the first antibody is reduced by at least 30%, usually at least about 40%, 50%, 60%, or 75%, and often at least about 90% using any of the above assays.

[0065] In some embodiments, the antibody (e.g., an anti-CD94 antibody) is linked to a toxin, e.g., a cytotoxin, such that the antibody binds to and kills NK cells (e.g., cells expressing CD94). Exemplary toxins include amanitin, anthracyclines, auristatins, baccatins, calicheamicins, camptothecins, cemadotins, colchicine, colcimids, combretastatins, cryptophycins, discodermolides, duocarmycins, echinomycins, eleutherobins, epothilones, estramustine, lexitropsis, and the like. Toxins may include, but are not limited to, benzodiazepines, maytansinoids, netropsin, puromycin, pyrrolobenzodiazepines, rhizoxin, taxanes, tubulysin, and vinca alkaloids. For example, as known in the art, the toxin can be linked to the antibody via a linker. See, for example, European Patent Application EP3165237A1. In some embodiments, the toxin is linked to the antibody via a natural or engineered cysteine ​​residue in the antibody, for example, in the Fc region.

[0066] In some embodiments, the antibody may have an increased half-life due to modification or fusion with a moiety or amino acid sequence that increases its serum half-life. In some embodiments, the antibody is pegylated or contains at least one binding site for binding to a serum protein (e.g., serum albumin) or other moiety (particularly at least one amino acid sequence) that increases the half-life of the antibody. Examples include, but are not limited to, serum albumin (e.g., human serum albumin), serum immunoglobulins such as IgG, or transferrin; an Fc portion (e.g., human Fc) or a suitable portion or fragment thereof; or one or more small proteins or peptides that can bind to serum proteins, such as, but not limited to, the proteins and peptides described in WO91 / 01743, WO01 / 45746, WO02 / 076489, WO08 / 068280, WO09 / 127691, and WO11 / 095545.

[0067] In some embodiments, the two portions of the polypeptide, for example, linking a variable domain to another sequence (e.g., a second variable region, or a half-life-enhancing or other sequence), may be linked directly to each other or may be linked to each other via one or more suitable spacers or linkers. Preferably, the linker or spacer is suitable for use in constructing proteins or polypeptides intended for pharmaceutical use. Some particularly preferred spacers include spacers and linkers used in the art to link antibody fragments or antibody domains. For example, the linker may be any suitable amino acid sequence, in particular an amino acid sequence of 1 to 50, preferably 1 to 30, e.g., 1 to 10 amino acid residues. Some examples of such amino acid sequences include gly-ser linkers, e.g., of the type described in WO99 / 42077 (gly). x ser y )2, such as (e.g., (gly4ser)3 or (gly3ser2)3, and the GS30, GS15, GS9, and GS7 linkers described in WO06 / 040153 and WO06 / 122825), and hinge-like regions, such as the hinge region of a native heavy chain antibody or an analogous sequence (e.g., as described in WO94 / 04678).

[0068] In some embodiments, an anti-CD94 antibody or an antibody that preferentially binds to natural killer cells is administered in conjunction with checkpoint inhibitor therapy. The anti-CD94 antibody can be administered before, after, or during the administration of one or more checkpoint inhibitors. Thus, in some embodiments, the checkpoint inhibitor is selected from a PD-1 inhibitor, a PD-L1 inhibitor, and a CTLA-4 inhibitor, or a combination thereof. Exemplary inhibitors may include, but are not limited to, antibodies that bind to the immune pathway checkpoint protein in question (e.g., PD-1, PD-L1, or CTLA-4) and block receptor-ligand binding. PD-1 and CTLA-4 inhibition are discussed, for example, in Buchbinder and Desai, Am J Clin Oncol. 2016 Feb; 39(1): 98-106. Exemplary CTLA-4 antibodies include, but are not limited to, ipilimumab (trade name Yervoy™) and those described, for example, in WO2001 / 014424, U.S. Patent No. US 7,452,535; US 5,811,097. Exemplary PD-1 antibodies include, but are not limited to, pembrolizumab (formerly MK-3475 and lambrolizumab, trade name Keytruda™), nivolumab (Opdivo), and cemiplimab (Libtayo), and those described, for example, in U.S. Patent No. 8,008,449 and Zarganes-Tzitzikas, et al., Journal Expert Opinion on Therapeutic Patents Volume 26, 2016, Issue 9. Exemplary PD-L1 antibodies include, but are not limited to, atezolizumab (Tecentriq), avelumab (Bavencio), and durvalumab (Imfinzi).

[0069] Polynucleotides (e.g., DNA) encoding the antibodies described herein are also provided, e.g., encoding the CDRs and optionally the entire variable regions described herein. Vectors (e.g., plasmids, viral vectors, etc.) containing polynucleotide sequences encoding the antibodies described herein are also provided, optionally with a promoter operably linked to the polynucleotide for expression within the cell. Prokaryotic cells (e.g., E. coli) or eukaryotic cells (e.g., mammalian, human, insect, plant, or yeast cells) containing the polynucleotide or vector are also provided.

[0070] In one aspect, one or more antibodies described herein are formulated as pharmaceutical compositions in therapeutically effective amounts, e.g., using a dosing regimen suitable for treating cancer or for reducing or preventing an immune response to transplanted cells or tissues in an individual. The compositions can be formulated for use in a variety of drug delivery systems.

[0071] Pharmaceutical compositions may contain pharmaceutically acceptable carriers. Pharmaceutically acceptable carriers are determined in part by the specific composition being administered and the specific method used to administer the composition. Thus, there are a wide variety of suitable formulations of pharmaceutical compositions of the present invention (see, for example, Remington's Pharmaceutical Sciences, 17th ed., 1989).

[0072] For administration by inhalation, the composition, alone or in combination with other suitable components, can be made into an aerosol formulation (i.e., "nebulized"). The aerosol formulation can be placed into a pressurized acceptable propellant, such as dichlorodifluoromethane, propane, and nitrogen. In some embodiments, the aerosol formulation is delivered to a subject by an inhaler. Thus, in some embodiments, an inhaler containing a pharmaceutical formulation comprising an antibody described herein is provided.

[0073] Formulations suitable for administration include aqueous and non-aqueous solutions, isotonic sterile solutions (which may contain antioxidants, buffers, bacteriostats, and solutes that render the formulation isotonic), and aqueous and non-aqueous sterile suspensions that may contain suspending agents, solubilizers, thickeners, stabilizers, and preservatives. In the practice of the present invention, the compositions can be administered, for example, orally, intranasally, topically, intravenously, intraperitoneally, or intrathecally. The compound formulations can be provided in unit-dose or multi-dose sealed containers, such as ampoules and vials. Solutions and suspensions can be prepared from sterile powders, granules, and tablets of the type previously described. The compositions can also be administered as part of a prepared food or drug.

[0074] In the context of the present method and composition, the dose administered to a patient must be sufficient to produce beneficial responses in the subject over time.The optimal dose level for any patient depends on various factors, including the efficacy of the specific modulator used, the patient's age, weight, physical activity and diet, and the possible combination with other drugs.The size of the dose is also determined by the existence, nature and extent of any adverse side effects associated with the administration of a specific compound or vector in a specific subject.

[0075] In determining the effective amount of an active ingredient (e.g., an antibody) to be administered, a physician may assess the circulating plasma level of the active ingredient and its toxicity. Generally, the dose equivalent of an antibody is about 1 ng / kg to 10 mg / kg for a typical subject. Administration can be accomplished in a single dose or in divided doses.

[0076] The compositions may be administered periodically (e.g., daily) over a period of time (e.g., 2, 3, 4, 5, 6 days, or 1-3 weeks or longer). The compositions may be administered directly to a mammalian subject to deplete natural killer cells using any route known in the art, including, for example, by injection (e.g., intravenous, intraperitoneal, subcutaneous, intramuscular, or intradermal), inhalation, or transdermal application.

[0077] Subjects who receive the antibodies described herein may include subjects who have been diagnosed with cancer. Tumors are classified as either benign or malignant depending on whether they can spread by invasion and metastasis. That is, benign tumors are tumors that cannot spread by invasion or metastasis. That is, benign tumors can only grow locally. In contrast, malignant tumors are tumors that can spread by invasion and metastasis. The methods described herein are useful for treating localized tumors and malignant tumors. Exemplary types of cancer include breast cancer; biliary tract cancer; bladder cancer; brain cancer, including glioblastoma and medulloblastoma; cervical cancer; choriocarcinoma; colon cancer; endometrial cancer; esophageal cancer; gastric cancer; hematologic malignancies, including acute lymphocytic leukemia and acute myeloid leukemia; T-cell acute lymphoblastic leukemia / lymphoma; hairy cell leukemia; chronic myelogenous leukemia, multiple myeloma; AIDS-related leukemia and adult T-cell leukemia / lymphoma; intraepithelial neoplasia, including Bowen's disease and Paget's disease; liver cancer; lung cancer; lymphomas, including Hodgkin's disease and lymphocytic lymphoma; neuroblastoma; oral cancer, including squamous cell carcinoma; Cancers include, but are not limited to, ovarian cancer, including ovarian cancer arising from epithelial cells, stromal cells, germ cells, and mesenchymal cells; pancreatic cancer; prostate cancer; rectal cancer; sarcoma, including leiomyosarcoma, rhabdomyosarcoma, liposarcoma, fibrosarcoma, and osteosarcoma; skin cancer, including melanoma, Merkel cell carcinoma, Kaposi's sarcoma, basal cell carcinoma, and squamous cell carcinoma; testicular cancer, including germ cell tumors, such as seminoma, non-seminoma (teratoma, choriocarcinoma), stromal tumor, and germ cell tumor; thyroid cancer, including thyroid adenocarcinoma and medullary carcinoma; and kidney cancer, including adenocarcinoma and Wilms' tumor. Other cancers are known to those skilled in the art.

[0078] In some embodiments, the cells introduced into an individual contain a heterologous protein expressed by a heterologous nucleic acid. Non-limiting examples of suitable methods for introducing nucleic acids into cells include electroporation (e.g., nucleofection), virus or bacteriophage infection, transfection, conjugation, protoplast fusion, lipofection, calcium phosphate precipitation, polyethyleneimine (PEI)-mediated transfection, DEAE-dextran-mediated transfection, liposome-mediated transfection, particle gun technology, calcium phosphate precipitation, direct microinjection, nanoparticle-mediated nucleic acid delivery, etc. In some embodiments, the polynucleotide encoding the protein is delivered to the cell by a vector. For example, in some embodiments, the vector is a viral vector. Exemplary viral vectors may include, but are not limited to, adenoviral vectors, adeno-associated viral (AAV) vectors, and lentiviral vectors.

[0079] Currently, CAR T cell products are made from autologous T cells. Approved for clinical use, these CAR T cells must be custom-made. This case-by-case autologous T cell production platform remains a major limiting factor for large-scale clinical use due to the costly and time-consuming production process. There is also an inherent risk of production failure. The personalized, custom-made autologous CAR T cell production process also inhibits widespread application against diverse tumor types. Therefore, universal allogeneic T cells are needed to prepare universal CAR T cells that can serve as "off-the-shelf" ready-to-use therapeutic agents for large-scale clinical use. Transient depletion of NK cells allows universal CAR T cell engraftment. Depleting NK cells in a host is particularly useful if allogeneic T cells have been engineered (e.g., by CRISPR) to eliminate expression of HLA class I proteins by disabling the b2-microglobulin gene or by disabling HLA class I heavy chain genes, e.g., HLA-A, HLA-B, HLA-C, or other polymorphic HLA class I genes, since NK cells preferentially kill HLA class I-negative cells. In some embodiments, depletion of NK cells enhances the expansion of autologous CAR T cells in a patient by deleting NK cells that can kill highly activated autologous T cells.

[0080] In some embodiments, after administration of an anti-NK cell antibody (e.g., an anti-CD94 antibody) and subsequent depletion of mature NK cells, the newly generated NK cells can become tolerant to the transferred allogeneic cells or tissue, e.g., HLA class I-negative cells or tissue.

[0081] Optionally, cells (e.g., CAR T cells or other T cells) introduced into the animal can be modified, for example, by CRISPR, to disable the CD94 (KLRD1) gene in these cells, thereby avoiding the potential toxic effects of anti-CD94 antibodies on the introduced cells in situations where activated CAR T cells have acquired CD94 expression.

[0082] Chimeric antigen receptors (CARs) are recombinant receptor constructs (e.g., nanobodies) that contain an extracellular antigen-binding domain joined to a transmembrane domain and further linked to an intracellular signaling domain (e.g., the intracellular T cell signaling domain of a T cell receptor component and the intracellular domain of a costimulatory receptor, e.g., CD28 or CD137) that signals and induces a function. In certain embodiments, immune cells (e.g., T cells or natural killer (NK) cells) are genetically engineered to express a CAR containing one or more antigen recognition domains and have effector cell function (e.g., the cytotoxic and / or memory function of T cells or NK cells).

[0083] Any suitable transmembrane domain for use in a CAR construct can be used. Such transmembrane domains include, but are not limited to, all or part of the transmembrane domains of the α, β, or ζ chains of the T cell receptor, CD28, CD27, CD3ε, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, and CD154. In some aspects, the transmembrane domain comprises at least one of the following: e.g., KIRDS2, OX40, CD2, CD27, LFA-1 (CD11a, CD18), ICOS (CD278), 4-1BB (CD137), GITR, CD40, BAFFR, HVEM (LIGHTR), SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD160, CD19, IL2Rβ, IL2Rγ, IL7Rα, ITGAl, VLAl, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD1D, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD1 The transmembrane region may include lc, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, TNFR2, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRT AM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100, (SEMA4D), SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME, (SLAMF8), SELPLG (CD162), LTBR, ​​PAG / Cbp, NKG2D, or NKG2C. [Example]

[0084] Example 1 CD94 is a membrane protein present on the surface of NK cells and is upregulated in activated NK cells. To generate antibodies against CD94, we expressed the CD94 ectodomain as an Fc fusion protein in mammalian cells and used this protein for phage display selection using a fully validated synthetic Fab phage library. Two recombinant monoclonal antibodies (JLS002-rAB22 and JLS002-rAB23) were generated and validated. Their CDR sequences were determined as follows: Both antibodies have high affinity and excellent expression and production in E. coli and mammalian cells. IgG and Fab fragments (fragment antigen-binding domains) of the two antibodies were generated. They showed excellent binding to CD94 and the CD94-NKG2C complex expressed on Ba / F3 cells, indicating their potential as therapeutic antibodies and components in research reagents.

[0085] 1. Expression and purification of Fc fusion proteins CD94 is a type II membrane protein. We generated a biotinylated Fc fusion protein (hereafter referred to as "Fc-CD94") in which the CD94 extracellular domain is fused to the C-terminus of human IgG1 Fc. To generate sufficient protein compatible with our phage display selection, we optimized the vector to improve the efficiency of protein expression and purification. In our experiments, we purified 100-130 μg of Fc-CD94 protein with approximately 90% biotinylation from a 30 ml mammalian cell culture after transient transfection of Expi293 cells.

[0086] 2. Selection We performed direct selection against the Fc-CD94 fusion protein, and the enrichment for each selection round is shown in Figure 1.

[0087] A total of 54 hits were generated from the third and fourth rounds of selection. Two Fab phages with unique sequences were confirmed by sequencing. The two Fabs were expressed and purified. The binding affinity was confirmed by multipoint ELISA. The binding curves are shown in Figures 2A-B. Figures 2A-B show that these two Fabs have good affinity.

[0088] 3. IgG affinity The affinity of IgG for two binders, JLS002-rAB22 and JLS002-rAB23, was measured using an Octet assay (see Figure 3). The affinity of IgG for two binders, JLS002-rAB22 and JLS002-rAB23, was measured using an Octet RED384 (ForteBio) instrument. Fc-CD94 fusion protein was immobilized on a streptavidin-coated BioLayer Interferometric Biosensor. After blocking with PBST buffer (PBS + 0.5 Tween) containing 10 μM biotin, the IgG being tested was loaded for 15 minutes and then exchanged for PBST buffer without IgG for approximately 30 minutes. Kinetic binding curves were recorded.

[0089] Lanier, LL, BC Corliss, J. Wu, and JH Phillips. 1998. Association of DAP12 with activating CD94 / NKG2C NK cell receptors. Immunity 8:693-701. PMID: 9655483. Mouse Ba / F3 cells were stably transduced with a retroviral vector encoding human CD94, or human CD94, human NKG2C, and human DAP12. Using standard methods, Ba / F3 transfectants were incubated with phosphate-buffered saline (unstained) or with rab22 JIS002 rab22 or JSI002 rab23 antibodies, washed, and then stained with PE-conjugated anti-human IgG1. Results are shown in Figure 4A-B.

[0090] Example 2 NK cell depletion was shown to improve the efficacy of α-PD-1L checkpoint blockade treatment against RMA tumor growth. C57BL / 6 mice were subcutaneously injected with 1x10e6 RMA lymphoma cells on day 0. As shown in Figure 5A, the experimental design included treating mice with a depleting anti-NK1.1 monoclonal antibody (clone PK136), which binds to an NK cell-specific protein on mouse natural killer cells, on days 0 and 7. Mice were administered α-PD-1L antibody (clone 10F.9G2) or a control rat IgG2b isotype-matched antibody on days 3, 4, 5, 7, and 10. Intraperitoneal injections of 150 μg, 250 μg, and 250 μg of α-NK1.1, α-PD-1L, or an IgG2b isotype-matched control antibody dissolved in saline were administered at the indicated time points. Time course measurements of tumor burden in mice under various treatments were performed. Figure 5B shows a graph of the resulting data. This shows that depletion of NK cells with anti-NK cell antibodies significantly reduced tumor burden in mice treated with checkpoint blockade α-PD-1L antibodies compared to controls. Significance is indicated by *P<0.05 by Student's t-test.

[0091] One or more features from any embodiment described in this specification or drawings may be combined with one or more features of any other embodiment described in any drawing of this specification without departing from the scope of the present disclosure.

[0092] All publications, patents, and patent applications cited in this specification are incorporated by reference herein as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference. Although the foregoing disclosure has been described in some detail by way of illustration and example, for purposes of clarity of understanding, it will be readily apparent to those skilled in the art, upon consideration of the present disclosure, that certain changes or modifications can be made therein without departing from the spirit or scope of the appended claims.

Claims

1. A pharmaceutical composition for treating cancer by enhancing a T cell response in an individual in need thereof, the pharmaceutical composition comprising a natural killer cell-specific antibody in an amount sufficient to deplete natural killer cells in the individual.

2. The pharmaceutical composition of claim 1, wherein the natural killer cell-specific antibody is an anti-CD94 specific antibody.

3. The pharmaceutical composition of claim 1 or 2, wherein the activated T cells in the individual target cancer cells in the individual.

4. A pharmaceutical composition described in any one of claims 1 to 3, for use in combination with one or more checkpoint inhibitors, wherein the one or more checkpoint inhibitors are administered to the individual before, after or simultaneously with administration of the natural killer cell-specific antibody, and optionally the checkpoint inhibitor is an anti-CTLA-4, anti-PD-1, or anti-PD-L1 antibody.

5. The antibody, a heavy chain variable region comprising a heavy chain complementarity determining region (CDR) 1 of SEQ ID NO:7, a heavy chain CDR2 of SEQ ID NO:8, and a heavy chain CDR3 of SEQ ID NO:9, and a light chain variable region comprising a light chain CDR1 of SEQ ID NO:10, a light chain CDR2 of SEQ ID NO:11, and a light chain CDR3 of SEQ ID NO:12; or a heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO:1, a heavy chain CDR2 of SEQ ID NO:2, and a heavy chain CDR3 of SEQ ID NO:3, and a light chain variable region comprising a light chain CDR1 of SEQ ID NO:4, a light chain CDR2 of SEQ ID NO:5, and a light chain CDR3 of SEQ ID NO:

6.

4. The pharmaceutical composition of claim 2 or 3, comprising:

6. the antibody is a chimeric antibody, optionally wherein the chimeric antibody is a humanized antibody, or The antibody is a human antibody or a synthetic antibody. A pharmaceutical composition according to any one of claims 1 to 5.

7. The antibody, a heavy chain variable region comprising SEQ ID NO:15 and a light chain variable region comprising SEQ ID NO:16; or A heavy chain variable region comprising SEQ ID NO:13 and a light chain variable region comprising SEQ ID NO:14 4. The pharmaceutical composition of claim 1 or 3, comprising:

8. the antibody induces antibody-dependent cellular cytotoxicity (ADCC) or antibody-dependent phagocytosis (ADP); or the antibody is linked to a toxin; A pharmaceutical composition according to any one of claims 1 to 7. (A) improving the survival of autologous or allogeneic cells transplanted into an individual; or (B) reducing or preventing natural killer cell rejection of allogeneic cell or tissue transplants in an individual. A pharmaceutical composition for treating cancer by a natural killer cell-specific antibody in an amount sufficient to transiently deplete natural killer cells in the individual receiving the transplanted cells before, after, or during administration of the natural killer cell-specific antibody. The pharmaceutical composition comprising:

10. The method of claim 1, wherein the natural killer cell-specific antibody is an anti-CD94 specific antibody, and / or The transplanted cells are autologous or allogeneic T cells or CAR T cells.

10. The pharmaceutical composition of claim 9.

11. 11. The pharmaceutical composition of claim 9 or 10, wherein the cells transplanted into the individual are allogeneic cells, and the allogeneic cells lack HLA class I proteins.

12. The transplanted cells are An introduced genetic alteration that blocks or reduces CD94 expression on the transplanted cells.

12. The pharmaceutical composition of claim 10 or 11, comprising: (a) The antibody, a heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO:7, a heavy chain CDR2 of SEQ ID NO:8, and a heavy chain CDR3 of SEQ ID NO:9, and a light chain variable region comprising a light chain CDR1 of SEQ ID NO:10, a light chain CDR2 of SEQ ID NO:11, and a light chain CDR3 of SEQ ID NO:12; or a heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO:1, a heavy chain CDR2 of SEQ ID NO:2, and a heavy chain CDR3 of SEQ ID NO:3, and a light chain variable region comprising a light chain CDR1 of SEQ ID NO:4, a light chain CDR2 of SEQ ID NO:5, and a light chain CDR3 of SEQ ID NO:

6. and / or (b) the antibody is a chimeric antibody, optionally wherein the chimeric antibody is a humanized antibody or wherein the antibody is a human antibody or a synthetic antibody; and / or (c) the antibody a heavy chain variable region comprising SEQ ID NO:15 and a light chain variable region comprising SEQ ID NO:16; or A heavy chain variable region comprising SEQ ID NO:13 and a light chain variable region comprising SEQ ID NO:14 and / or (d) the antibody induces antibody-dependent cellular cytotoxicity (ADCC) or antibody-dependent phagocytosis (ADP), or the antibody is linked to a toxin; 13. The pharmaceutical composition according to any one of claims 9 to 12.

14. The pharmaceutical composition of claim 10, wherein the individual is administered an anti-CD94 specific antibody prior to transplantation and then transplanted with allogeneic cells or tissue while natural killer cells are depleted.

15. A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO:7, a heavy chain CDR2 of SEQ ID NO:8, and a heavy chain CDR3 of SEQ ID NO:9, and a light chain variable region comprising a light chain CDR1 of SEQ ID NO:10, a light chain CDR2 of SEQ ID NO:11, and a light chain CDR3 of SEQ ID NO:12; or a heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO:1, a heavy chain CDR2 of SEQ ID NO:2, and a heavy chain CDR3 of SEQ ID NO:3, and a light chain variable region comprising a light chain CDR1 of SEQ ID NO:4, a light chain CDR2 of SEQ ID NO:5, and a light chain CDR3 of SEQ ID NO:

6.

1. A monoclonal antibody that binds to CD94, comprising: Optionally, (i) the antibody is a chimeric antibody, such as a humanized antibody; or (ii) the antibody a heavy chain variable region comprising SEQ ID NO:15 and a light chain variable region comprising SEQ ID NO:16; or A heavy chain variable region comprising SEQ ID NO:13 and a light chain variable region comprising SEQ ID NO:14 Contains; The monoclonal antibody.